Study of the tumor microenvironment during breast cancer progression

[1]  B. Czerniecki,et al.  Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential. , 2016, Immunotherapy.

[2]  R. Kiessling,et al.  Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer , 2016, Journal of Translational Medicine.

[3]  R. Baharlou,et al.  Reduced levels of T-helper 17-associated cytokines in the serum of patients with breast cancer: indicators for following the course of disease , 2016, Central-European journal of immunology.

[4]  Mingyong Han,et al.  Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. , 2015, Molecular medicine reports.

[5]  G. Aprile,et al.  Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? , 2015, Expert review of clinical pharmacology.

[6]  J. Morales-Montor,et al.  The role of cytokines in breast cancer development and progression. , 2015, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[7]  Bing-lin Fan,et al.  Overexpression of VEGF183 promotes murine breast cancer cell proliferation in vitro and induces dilated intratumoral microvessels , 2015, Tumor Biology.

[8]  A. Edelman,et al.  How can we improve oral contraceptive success in obese women? , 2015, Expert review of clinical pharmacology.

[9]  M. Karin,et al.  Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. , 2014, Immunity.

[10]  S. Negrotto,et al.  Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L , 2014, Cell Death and Disease.

[11]  R. Rong,et al.  Skewed T-helper (Th)1/2- and Th17/T regulatory-cell balances in patients with renal cell carcinoma , 2014, Molecular medicine reports.

[12]  S. Leung,et al.  Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration , 2014, Breast Cancer Research.

[13]  Ruo-Pan Huang,et al.  Tumor-induced perturbations of cytokines and immune cell networks. , 2014, Biochimica et biophysica acta.

[14]  A. Barberà,et al.  IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis , 2014, Tumor Biology.

[15]  P. Argani,et al.  Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. , 2013, Human pathology.

[16]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[17]  M. Dobrzanski.  Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy , 2013, Front. Oncol..

[18]  M. Núñez,et al.  Tumor microenvironment and breast cancer progression , 2012, Cancer biology & therapy.

[19]  L. Coussens,et al.  Immune microenvironments in solid tumors: new targets for therapy. , 2011, Genes & development.

[20]  J. Hicks,et al.  Insight into the heterogeneity of breast cancer through next-generation sequencing. , 2011, The Journal of clinical investigation.

[21]  H. Alshaker,et al.  IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors , 2011, Cancer Cell International.

[22]  Keivan Majidzadeh-A,et al.  TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer , 2011, BMC Research Notes.

[23]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[24]  S. Coughlin,et al.  Breast cancer as a global health concern. , 2009, Cancer epidemiology.

[25]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[26]  J. Talmadge,et al.  Inflammatory cell infiltration of tumors: Jekyll or Hyde , 2007, Cancer and Metastasis Reviews.

[27]  L. Coussens,et al.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.

[28]  R. Carlson,et al.  Breast Cancer in Limited‐Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines , 2006, The breast journal.

[29]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[31]  S. Takeno,et al.  Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. , 2003, Oncology reports.

[32]  B. Sheu,et al.  Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in Human Cervical Cancer1 , 2001, The Journal of Immunology.

[33]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[34]  A. Ohta,et al.  Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.

[35]  Charushila Y. Kadam,et al.  Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[36]  B. Shan,et al.  Expression of Th17 Cells in Breast Cancer Tissue and Its Association with Clinical Parameters , 2011, Cell Biochemistry and Biophysics.

[37]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[38]  Lisa M. Coussens,et al.  Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007 .

[39]  T. Whiteside,et al.  The role of immune cells in the tumor microenvironment. , 2006, Cancer treatment and research.

[40]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[41]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.